Abel Hall LLC
PACB icon

Abel Hall LLC’s Pacific Biosciences PACB Stock Holding History

Abel Hall LLC’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$26.7K Sell
11,278
-3,685
-25% -$5.2K ﹤0.01% 862
2026
Q2 		$25.1K Sell
14,963
-7,736
-34% -$11.2K ﹤0.01% 936
2026
Q1 		$30K Buy
22,699
+6,208
+38% +$11.1K 0.01% 775
2025
Q4 		$30.8K Buy
16,491
+5,403
+49% +$10.4K 0.01% 683
2025
Q3 		$14.2K Sell
11,088
-895
-7% -$1.21K 0.01% 319
2025
Q2 		$14.9K Buy
+11,983
New +$13.8K 0.01% 273

Other funds holding PACB

Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return
Mirador Capital Partners
Mirador Capital Partners Pleasanton, California $859M AUM 41.74% 1-Year Est. Return
Advisornet Financial
Advisornet Financial Minnetonka, Minnesota $2.21B AUM 14.38% 1-Year Est. Return
Koa Wealth Management
Koa Wealth Management Encinitas, California $154M AUM 13.16% 1-Year Est. Return
Caitong International Asset Management
Caitong International Asset Management Hong Kong $1.04B AUM 150.25% 1-Year Est. Return
ProShare Advisors
ProShare Advisors Bethesda, Maryland $69.5B AUM 31.38% 1-Year Est. Return
China Universal Asset Management Company
China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return
Green Alpha Advisors
Green Alpha Advisors Niwot, Colorado $148M AUM 98.22% 1-Year Est. Return
Venture Visionary Partners
Venture Visionary Partners Sylvania, Ohio $3.82B AUM 21.33% 1-Year Est. Return
Private Wealth Partners
Private Wealth Partners Mill Valley, California $1.47B AUM 33.05% 1-Year Est. Return

Abel Hall LLC's PACB Position: Q3 2026 in Review

Abel Hall LLC reduced its Pacific Biosciences (PACB) stake by 25% in Q3 2026, selling an estimated $5.2K and leaving 11,278 shares worth $26.7K. The position accounts for ﹤0.01% of the portfolio, ranked #862.

Abel Hall LLC first reported a position in PACB in Q2 2025 and has held it in 6 quarters since. The position peaked at $30.8K in Q4 2025. 34 funds tracked by Wall St. Rank hold PACB as of Q3 2026.

  • Abel Hall LLC held 11,278 shares of Pacific Biosciences worth $26.7K as of Q3 2026.
  • Abel Hall LLC sold 3,685 Pacific Biosciences shares in Q3 2026, an estimated $5.2K.
  • Pacific Biosciences made up ﹤0.01% of Abel Hall LLC's portfolio in Q3 2026, its #862 holding.
  • Abel Hall LLC first reported a position in Pacific Biosciences in Q2 2025 and has held it in 6 quarters since.
  • Abel Hall LLC's Pacific Biosciences position peaked at $30.8K in Q4 2025.
  • 34 funds tracked by Wall St. Rank held Pacific Biosciences as of Q3 2026.

Based on Abel Hall LLC's 13F filing for Q3 2026, filed 19 Oct 2026.